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Introduction

E
pidermal growth factor receptor-2 (EGFR-2, erythroblastic leukemia viral oncogene homolog 2 ) is a member of the EGFR family of transmembrane receptor tyrosine kinases.
1,2 EGFR-2 expression has been reported to be minimal in normal tissues, 3 however, amplification of this receptor occurs in approximately 30% of invasive breast cancers and is associated with poor patient outcome.
imaging and therapy. In the past few years, several groups have developed antibodies, scFV fragments, and peptides [7] [8] [9] [10] that bind to EGFR-2.
Bacteriophage (phage) display libraries have been extensively used to identify peptides that bind to a variety of targets including EGFR-2.
11-13 Such phage-derived peptides, once radiolabeled, hold promise as effective imaging agents for identifying specific human tumors and evaluating response to therapy. Although many imaging agents have been developed using antibodies and proteins, they often demonstrate low specificity, poor accumulation in target tissue, sensitivity to reaction conditions, and slow clearance properties in vivo. 14, 15 Accordingly, the number of radiopharmaceutials utilizing bifunctional chelator-conjugated peptides for use in imaging has grown considerably over the past few decades. 16, 17 Previously, we reported an 111 Inlabeled phage display selected peptide, KCCYSL, for single photon emission computed tomography (SPECT) imaging of EGFR-2 expressing human breast tumor xenografts in mice. 18 However, due to the inherent limited sensitivity and resolution of SPECT imaging, we were interested in evaluating KCCYSL peptide for the positron emission tomography (PET) targeted imaging of EGFR-2 expressing tumor(s).
PET imaging depends on the delivery of a targeting ligand containing a positron emitting radionuclide to a tissue or organ of interest. Copper-64 (t 1/2¼ 12.7 hours) is an attractive radionuclide for PET imaging that can be used for both diagnostic imaging and radionuclide therapy due to its dual decay characteristics. 19 The positron emissions (b þ :17.8%, E bþmax¼ 653 keV; b À : 38.4%, E b-max¼ 578 keV) would allow clinicians to image a patient using PET and provide therapeutic treatment using the same 64 Cu-targeted pharmaceutical. Unfortunately, the application of 64 Cu-based radiopharmaceuticals has been hindered by the lack of stable copper radiotracers in vivo. The high uptake and retention of coppercontaining compounds in the blood and liver are well known. 20, 21 Therefore, more stable chelator-compounds are necessary for in vivo studies using 64 Cu. Macrocyclic polyamine complexes of 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetracetic acid (TETA) and 1,4,7,10, tetraazacyclododecane-N,N',N'',N'''-tetracetic acid (DOTA) with copper have been shown to exhibit greater kinetic inertness than acyclic analogs, but dissociation of copper from both the chelators occurs in vivo. [22] [23] [24] Weisman, Wong, and Anderson designed and characterized the novel cross-bridged tetraaza-macrocyclic chelator 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid (CB-TE2A) and demonstrated enhanced in vivo stability with significantly less transchelation in the liver compared with 64 Cu-TETA. Thus, the rigidity of the cross-bridge system was credited for the greater kinetic stability of the copper (II)-CB-TE2A complex. 25, 26 Previous studies have also demonstrated the use of 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), a 9-member cyclic chelating agent for divalent copper. [27] [28] [29] NOTA was shown to have the capacity to form stable metal complex with Cu 2þ and other divalent and trivalent metals, 29 which overcome demetallation and tracer uptake in tissues such as liver. Functionalized NOTA derivatives suitable for conjugation with proteins or peptides have been reported by different groups. 29, 30 In this study, we evaluated and compared the in vitro and in vivo properties of DO3A-GSG-KCCYSL, CB-TE2A-GSG-KCCYSL, and NO2A-GSG-KCCYSL radiolabeled with 64 Cu. The radiolabeled peptides were tested for cell binding, stability, pharmacokinetics, and tumor imaging in MDA-MB-435 human breast carcinoma xenografted mice using small-animal PET/CT.
Materials and Methods
Reagents, cell lines, and animals
Reverse phase-high performance liquid chromatography (RP-HPLC)-grade acetonitrile, and trifluoroacetic acid were purchased from Fischer Scientific for HPLC analysis. Copper-64 was purchased from Nuclear Reactor Laboratory, University of Wisconsin. RPMI (Roswell Park Memorial Institute) 1640 and human mammary epithelial cell media were purchased from Invitrogen/Gibco. Bovine serum albumin (BSA) and trypsin were obtained from Sigma Chemical Company. DOTA was purchased from Macrocyclics, and CB-TE2A was synthesized as previously described. 31 NOTA was procured from Chematech.
Normal mammary 184A1 cell line was obtained from American Type Tissue Culture. The MDA-MB-435 cells were maintained as monolayer cultures in RPMI-1640 medium supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential amino acids, and l-glutamine. 184A1 cells were grown in (human mammary epithelial cell) media supplemented with bovine pituitary extract. Cell cultures were maintained at 378C in a 5% CO 2 humidified incubator. Sub-culturing was performed using standard trypsinization procedures.
Four-to 5-week-old ICR-SCID (Institute of Cancer Research severely compromised immunodeficient) female mice were obtained from Taconic Farms. The mice were supplied with sterilized water and irradiated rodent chow ad libitum. Under gas anesthesia, each SCID mouse was subcutaneously inoculated in the right shoulder with 1Â10 7 MDA-MB-435 cells. The tumors were allowed to grow for 3-4 weeks before studies were performed. Animal studies were conducted in accordance with the protocols approved by the institutional animal care and use committee in accordance with U.S. Public Health Service guidelines.
Solid-phase peptide synthesis
Peptides used in this study were synthesized using an Advanced Chem Tech 396 multiple peptide synthesizer (AAPP-TEC) using standard Fmoc chemistry. Briefly, the resin (50 mmol) was deprotected using piperidine, resulting in the formation of a primary amine from which the C-terminus of the growing peptide was anchored. The Fmoc protected amino acids (225 mmol) with appropriate orthogonal protection were activated using O-benzotriazole-N,N,N 0 , N 0 -tetramethyl-uronium-hexafluoro-phosphate, N-hydroxybenzotriazole, and N,N-diisopropylethylamine and sequentially added to the resin. The metal chelators DOTA or NOTA were coupled to the amino terminus of the linear GSG-KCCYSL. In the case of CB-TE2A, the chelator was coupled to the peptide on the resin through an intermediate preparation of the activated mixed anhydride by use of diisopropylcarbodiimide/ N,N-diisopropylethylamine/dimethylformamide as described earlier. 31 The resulting peptide was deprotected and cleaved from the resin using a cocktail consisting of thioanisol, water,
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1,2-ethanedithiol, phenol, triisopropylsilane (2.5 ratio each), and trifluoroacetic acid, respectively. The cleaved peptide was then precipitated and washed using ether. The crude conjugate was dried, weighed, and analyzed by Electrospray Ionization massspectrometry (Thermo Finnigan). A NovaPak (HR-C18, 7.8Â300 mm, 6 mM, 60 Å ) (Waters) column was used for the purification of bulk amounts of peptides. The peptides were peak purified to !98% purity before in vitro cell binding assays.
Radiolabeling of peptides with 64 Cu
Radiolabeling of DO3A-, CB-TE2A-, or NO2A-(GSG)-KCCYSL with 64 Cu was performed as follows: For DO3A-(GSG)-KCCYSL, the peptide (50 mg) was radiolabeled with 29. The reaction buffer was purged with nitrogen before radiolabeling to inhibit or minimize peptide oxidation. Also, as a precautionary measure, the reaction buffers contained 0.05 mM Tris-(2-carboxyethyl) phosphine hydrochloride (TCEP.HCl) to maintain cysteine reduction in the wake of radiolytic oxidation during the peptide metal chelation process. The resulting radiolabeled peptides were peak purified using a Phenomenex Jupiter 5u C18 300 Å 250Â4.6 mm column and RP-HPLC (10%-95% acetonitrile/0.1% TFA) for 30 minutes to separate them from their nonradiolabeled counterparts. The peak-purified peptides were concentrated using Empore high efficiency (C 18 ) extraction disk cartridges and eluted with 400 mL of an 8:2 ethanol/sterile saline solution. The ethanol was evaporated under a stream of nitrogen and was diluted to the appropriate volume with sterile saline. Radiochemical yields for 64 Cu-DO3A-, 64 Cu-CB-TE2A-, and 64 Cu-NO2A-GSG-KCCYSL averaged 55%, 45%, and 57%, respectively. Radiochemical purity of all 64 Cu-labeled peptides was found to be !98% pure. Cu-NO2A-GSG-KCCYSL peptides were dissolved separately in 500 mL of ammonium acetate buffer (purged with nitrogen and contained TCEP) with appropriate pH (as mentioned above) containing 0.8 mM copper(II) sulfate-pentahydrate solution. The solutions were heated at identical conditions used for radiolabeling procedure and allowed to cool to room temperature. nat Cu-peptides were then peak purified by RP-HPLC. The native ( nat Cu)-peptides were determined to be !98% pure by RP-HPLC analyses. Electrospray Ionization mass-spectrometry was performed to check the integrity of the peptides.
In vitro cell binding of radiolabeled KCCYSL peptides
Experiments were performed to test the ability of the radiolabeled peptides to bind cell lines that express low to moderate levels of EGFR-2 32 (MDA-MB-435) or normal mammary epithelial cells (184A1) with negligible EGFR-2 expression. Cells grown in culture flasks were trypsinized, released, and washed once in cell binding media (RPMI 1640 with 25 mM HEPES, 8 pH 7.4, 0.2% BSA, 3 mM 1, 10-phenanthroline). Cells (1Â10 5 cells/tube) were transferred to microcentrifuge tubes containing 0.3 mL cell binding medium and were incubated at 378C for different times (15 minutes, and 0.5, 0.75, 1, 1.5 and 2 hours) with 1Â10 5 counts per minute (cpm) of radiolabeled peptides. After incubation, the media were removed, and the cells were rinsed with icecold 0.01 M PBS, pH 7.4, 0.2% BSA, and centrifuged. This process was repeated twice. Radioactivity bound to the cells was quantified in a Wallac g counter (PerkinElmer Life and Analytical Sciences Inc.). Cell binding ability was reported as total radioactivity in cpm that was bound to the cells.
Fifty 
The cell-associated radioactivity was measured in a Wallac g counter, and the binding affinity was determined by the Grafit software program (Erithacus Software Limited).
In vitro serum stability of the radiolabeled peptides was tested by incubating 29.6 MBq of the respective peptide in 0.3 mL of mouse serum at 378C for 0.5, 1, 2, 4, and 24 hours, respectively. At various time points, 40 mL aliquots were removed, and the proteins were precipitated with 40 mL acetonitrile. The samples were centrifuged at 12,500 rpm for 5 minutes, and the cleared lysate (*40 mL aliquots) was analyzed by RP-HPLC with a 0%-95% gradient acetonitrile in 30 minutes to assess the integrity of the radiolabeled peptides.
Pharmacokinetic studies of 64 Cu-labeled peptides in MDA-MB-435 xenograft SCID mice SCID mice bearing MDA-MB-435 tumors (3 per time point) were injected with approximately 0.185 MBq of different radiolabeled peptides and were sacrificed by cervical dislocation at 30 minutes and 1, 2, 4, and 24 hours postinjection (p.i.), after which tissues and organs of interest were collected. Gastrointestinal tract contents were not removed. The animal, tissue, and organ samples were weighed, and counts were determined with an automated g counter. Uptake of radioactivity in the tumor and normal tissues and organs was expressed as a percentage of the injected radioactive dose per gram (%ID/g). Whole blood %ID or %ID/g was determined assuming the blood accounted for 6.5% of the body weight of the mouse. For blocking experiments, the MDA-MB-435 breast tumor-bearing mice (n ¼ 3) were preinjected with 100 mg of nat Cu-DO3A or nat Cu-CB-TE2A or nat Cu-NO2A peptides. After 10 minutes p.i., of the nonradiolabeled peptide, 0.185 MBq of radiolabeled counterpart was injected and the blocking efficiency was evaluated after 2 hours.
For reducing the kidney retention of the radiolabeled peptides in mice, inhibition experiments with albumin fragments were performed. 33 Briefly, 335 mg of trypsin was added to 3.0 g of BSA in 50 mM ammonium carbonate (15 mL). The mixture was incubated at 378C for 24 hours. The trypsindigested sample was filtered using 50 kDa Centripep (YM-50) centrifugal filters (Millipore). The filtrate containing albumin fragments <50 kDa was further fractionated using a YM-3 filter (3 kDa cutoff), which yielded albumin fragments <3 kDa (filtrate) and fragments with molecular weight range of 3-50 kDa (residue). The effect of inhibition on renal uptake of the radiolabeled peptides was tested in the presence of the 3-50 kDa albumin fraction.
In separate experiments, the 3-50 kDa albumin fragment (200 mg) sample in normal saline (100 mL) was preinjected into the MDA-MB-435 tumor-bearing mice (n ¼ 3) via the tail vein. After 5 minutes, 0.185 MBq of 64 Cu-DO3A-(GSG)-KCCYSL or 64 Cu-CB-TE2A-(GSG)-KCCYSL or 64 Cu-NO2A-(GSG)-KCCYSL was administered into the mice. The mice were sacrificed after 2 hours p.i., and the kidney uptake of the radiolabeled peptides was measured in a g-counter.
Control experiments (n ¼ 3) were run in parallel with preinjection of normal saline instead of albumin fragments.
MicroPET/CT imaging studies
In vivo microPET/CT of MDA-MB-435 tumor-bearing mice with the radiolabeled peptides were performed as follows. MDA-MB-435 tumor-bearing mice were injected in the tail vein with 12.0 MBq of 64 Cu-DO3A-or 64
Cu-CB-TE2A-or 64 Cu-NO2A-(GSG)-KCCYSL and imaged at 2 hours p.i., in a small animal PET scanner (MOSAIC small animal PET unit [Philips] ). This PET scanner has a transverse field of view of 12.8 cm and a gantry diameter of 21 cm. The scanner operates in a three-dimensional (3D) mode. The mouse to be imaged was laser aligned at the center of the scanner field of view for imaging. The microPET image reconstruction was performed with a 3D row-action maximum-likelihood algorithm. Small animal CT was performed for the purpose of anatomic/molecular data fusion, and concurrent image reconstruction was performed with a Fanbeam (Feldkamp) filtered-backprojection algorithm. Reconstructed Digital Imaging and Communication in Medicine PET images were imported into AMIRA 3.1 software (Visage Imaging, Inc.) for subsequent image fusion with microCT and 3D visualization.
Statistical analysis
The data are presented as mean AE standard deviation. For statistical analysis, a Student's t-test was performed using Prism software (Graphpad Software). A p-value 0.05 was considered significant.
Results
Preparation and characterization of different chelator-KCCYSL peptide
The peptides DO3A-(GSG)-KCCYSL, CB-TE2A-(GSG)-KCCYSL, and NO2A-(GSG)-KCCYSL were synthesized by solid-phase synthesis with GSG spacers between the chelators and the amino termini of the peptides to avoid possible steric hindrances. The chemical structures of different chelatorpeptides are shown in Figure 1 . Nonradioactive Cu-chelatorpeptides were prepared by heating aqueous solutions of the peptides with CuSO 4 .5H 2 O at temperatures similar to those described for radioactive peptides. Nonradiolabeled copperlabeled peptides were purified and analyzed by mass spectrometry before cell binding assays. The calculated and observed molecular weight of Cu-NO2A-GSG-KCCYSL were 12.8, 13.3, and 13.0 minutes, respectively, under identical RP-HPLC conditions. All the peptides were obtained at high radiochemical purity with a reasonable radiochemical yield (Table 1) .
Studies to test the ability of the 64 Cu-radiolabeled peptides to bind MDA-MB-435 breast carcinoma cells known to express EGFR-2 32 or normal mammary epithelial cells (184A1) with negligible expression of EGFR-2 were performed. The 64 Cu-DO3A, 64 Cu-CB-TE2A, and 64 Cu-NO2A peptides were able to bind EGFR-2 expressing MDA-MB-435 cells in a timedependent manner. The peptides exhibited a similar cell binding profile up to 45 minutes, beyond which binding of the peptides to MDA-MB-435 cells appeared to be saturated. Further increase in cell binding was not observed up to 2 hours (Fig. 2) . The peptides demonstrated less or no binding to 184A1 cells, indicating the specificity of the radiolabeled peptides for EGFR-2 expressing cells.
Receptor binding affinity studies with radiolabeled peptides in the presence of their respective nonradioactive counterparts were carried out using cultured human MDA-MB-435 breast carcinoma cells. To determine their metabolic stability, the radiolabeled peptides were incubated in mouse serum for various time points in vitro, at 378C. As determined by RP-HPLC, the radiolabeled peptides were stable in serum for periods up to 2 hours. However, an additional peak was observed with all three radiolabeled peptides, which eluted very close to the original radiolabeled peak, indicating degradation of peptide with passage of time at 4 and 24 hours (data not shown).
Biodistribution and imaging studies
Detailed in vivo pharmacokinetic studies with all the radiolabeled peptides in SCID mice bearing MDA-MB-435 xenografts were performed and are summarized in Tables 2-4 . At 2 hours p.i., 89.4 AE 3.6%ID had been excreted from the mice using 
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The disappearance of different radiolabeled peptides from the blood was comparable at initial time points (0.5, 1, and 2 hours) tested. For instance, at the end of 2 hours p.i., peptide retention in the blood was 0.20 AE 0.08%ID/g, 0.05 AE 0.01%ID/g, and 0.08 AE 0.01%ID/g for 64 Cu-DO3A-, 64 Cu-CB-TE2A-, and 64 Cu-NO2A-peptides, respectively. Despite lower blood values observed for CB-TE2A and NO2A peptides compared with DO3A-peptide at or beyond 2 hours time point, the values were not statistically different ( p > 0.05).
Unstable copper compounds are known to exhibit higher retention in the liver in vivo. In this study, the retention of 64 Cu in the liver with 64 Cu-DO3A-peptide was observed to be higher than 64 Cu-CB-TE2A-or 64 Cu-NO2A-peptide at all time points, suggesting the relative stable chelation of 64 Cu with CB-TE2A and NO2A. The difference in radiolabled uptake in the liver between 64 Cu-DO3A-and 64 Cu-CB-TE2A-peptide (n ¼ 3, p ¼ 0.001), 64 Cu-DO3A-, and 64 Cu-NO2A-peptide (n ¼ 3, p ¼ 0.03) was statistically different, whereas the uptake between Cu-NO2A-peptide). Also, in the later time points, there were no significant differences in the tumor uptake between the three radiolabeled peptides. For instance, at the 2 hours time point, the tumor uptake of The tumor-to-blood ratio was found to be significantly different between 64 Cu-DO3A/ 64 Cu-CB-TE2A peptides (n ¼ 3, p ¼ 0.04) and 64 Cu-DO3A/ 64 Cu-NO2A peptides (n ¼ 3, p ¼ 0.045), whereas there was no significant difference between 64 Cu-CB-TE2A/ 64 Cu-NOTA peptides for all time points ( p > 0.05). Similarly, tumor-to-liver ratios were also significantly different between 64 Cu-DO3A/ 64 Cu-CB-TE2A (n ¼ 3, p ¼ 0.027) and 64 Cu-DO3A/ 64 Cu-NO2A (n ¼ 3, p ¼ 0.01) peptides, respectively. These results suggest that 64 Cu-DO3A peptide uptake in the liver was high compared with 64 Cu-CB-TE2A and 64 Cu-NO2A peptides. However, no major difference was observed between 64 Cu-CB-TE2A and 64 Cu-NO2A peptides, suggesting their uptake was comparable in liver tissue at all time points. No variation in tumor-to-muscle ratio was observed between the three radiolabeled peptides (Tables 2-4) , and the differences in values were not statistically significant (n ¼ 3, p > 0.05). Increased tumor-to-liver tissue ratio of both 64 Cu-CB-TE2A and 64 Cu-NO2A peptides compared with 64 Cu-DO3A peptide suggests less transchelation of 64 Cu from the former two chelator-peptides.
The retention of radiolabeled peptides was observed to be high in kidneys. Radioactivity in the kidneys decreased from 6.37 AE 1.44%ID/g at 0.5 hours to 4.27 AE 0.84%ID/g at 2 hours and 1.49 AE 0.24%ID/g at 24 hours, for 64 Cu-DO3A-peptide. Similarly, the radioactivity declined from 7.11 AE 0.75%ID/g after 0.5 hours p.i., to 6.43 AE 1.56%ID/g at 2 hours, and 3.2 AE 0.23%ID/g at 24 hours for 64 Cu-CB-TE2A-peptide. 64 Cu-NO2A-peptide uptake in kidneys was 7.87 AE 0.96 at 0. Cu-CB-TE2A-peptides were comparable and did not significantly differ ( p > 0.05).
Blocking studies were performed with 100 mg of respective nat Cu-peptides 15 minutes before the injection of the radiolabeled peptides in tumor mice (n ¼ 3). As a positive control, another set of mice (n ¼ 3) was injected with respective radiolabeled peptides only. The results demonstrated that tumor uptake of radiolabeled peptide was blocked by 46% (DO3A-peptide, p ¼ 0.03), 50% (CB-TE2A-peptide, p ¼ 0.024), and 48% (NO2A-peptide, p ¼ 0.027), respectively (Tables 2-4) .
It is well known that high and persistent renal retention of radiolabeled peptides is a concern when designing receptortargeted radiopharmaceuticals. In an attempt to study an agent that could interfere with kidney retention of the radiolabeled peptides, albumin fragments 33 were used as inhibiting agents. The renal uptake of the radiolabeled peptides with and without albumin fragments (3-50 kDa) is shown in (Fig. 3) . The kidney retention of the radiolabeled peptides with Cu-NO2A-(GSG)-KCCYSL was blocked in the presence of albumin fragments by 29%, 47%, and 47.5% (n ¼ 3 each, p 0.05), respectively.
Observations from small animal microPET experiments performed in SCID mice bearing MDA-MB-435 tumors at different times after intravenous injection of 12.0 MBq of each 64 Cu-DO3A-, 64 Cu-CB-TE2A, and 64 Cu-NO2A-(GSG)-KCCYSL are depicted in Figure 4 . All the images were acquired at 2 hours p.i., of the radiolabeled peptides. Tumors could be easily visualized with radiolabeled peptides. For 64 Cu-DO3A-peptide, the abdominal uptake and retention appeared high compared with 64 Cu-CB-TE2A-and 64 Cu-NO2A-peptides, which showed relatively less retention in the gastrointestinal tract and liver. A more notable difference in retention was observed in liver tissue for the 64 Cu-DO3A-peptide,which was higher compared with 64 Cu-CB-TE2A-or 64 Cu-NO2A-KCCYSL, which agrees with the biodistribution data. Substantial uptake of all radiolabeled peptides in the kidneys was evident, indicating that theses tracers are mainly excreted through the renal route.
Discussion
Our study demonstrates that a phage derived peptide, KCCYSL, that binds the extracellular domain of EGFR-2, 11, 18 once synthesized with a bi-functional chelator and radiolabeled with 64 Cu, can be developed into a PET imaging agent for detection of breast tumors in vivo. Though other groups have reported peptides derived from phage display that bind EGFR-2, 13, 34, 35 our studies are the first to demonstrate in vivo in a animal model that an EGFR-2 targeting peptide selected by phage display can be exploited as an SPECT or PET radioimaging agent.
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DOT3A-(GSG)-KCCYSL, CB-TE2A-(GSG)-KCCYSL, and NO2A-(GSG)-KCCYSL were synthesized and efficiently radiolabeled with 64 Cu. One potential problem with cysteine-containing peptide(s) in aqueous buffers especially at neutral or alkaline pH is the oxidation of its thiol group to form disulfide bonds during radiolabeling reactions. Though the oxidation may be minimal in acidic pH (as in DO3A labeling), the chances are relatively high in near neutral pH such as the reaction conditions used in CB-TE2A and NO2A. To overcome this situation, the reaction buffers were extensively purged with nitrogen to keep oxygen levels minimal and also contained reducing agent TCEP to prevent the formation of disulfide bonds.
All the radiolabeled peptides bound to EGFR-2 expressing MDA-MB-435 breast carcinoma cells, whereas minimal binding was observed with normal mammary cells (184A1). MDA-MB-435 human breast carcinoma cells were originally isolated from a pleural effusion of a woman with metastatic breast adenocarcinoma. 36 Rae at al. speculated in 2004 that the original MDA-MB-435 cancer cells were lost early after their establishment and found to be identical to the M-14 melanoma cell line. 37 However, a recent report based on the different origin of these cell lines indicated that both MDA-MB-435 and M-14 cell lines are consistent with MDA-MB-435 breast cancer origin 38 and that some poorly differentiated breast tumors can exhibit lineage infidelity and express markers associated with both epithelial and melanomas. Given this, the MDA-MB-435 breast carcinoma cell line has been widely used as a breast carcinoma model and remains one of the most reliable in vivo models of human breast cancer.
In vitro competition studies with unlabeled peptides demonstrated specificity of the radiolabeled peptide for breast carcinoma cells. Comparable binding affinities were noted with the three radiolabeled peptides. One would anticipate that binding affinity differences between the peptides may arise due to the use of different chelators. Previous studies with somatostatin receptor targeting DOTA-[Tyr3]-octreotide peptide analogs suggested that relatively small changes in a radiolabeled peptide, such as altering the chelator, can markedly change the receptor binding profile. 39 
FIG. 3.
Renal blocking studies with bovine serum albumin fragments. Albumin fragments (200 mg) were preinjected in the mice 5 minutes before the injection of radiolabeled peptides (0.185 MBq). The kidney uptake of the radioligands in mice with and without albumin fragments was measured in a g-counter. Inhibition in the uptake of Similar to radiolabeled GSG-KCCYSL peptides, corresponding nonradiolabeled peptides presumably undergo faster blood clearance, and demetallation from these peptides may also occur in the liver. This presumably could have been attributed to partial blocking of tumoral uptake of the radiolabeled peptides in the presence of their nonradiolabeled counterparts during biodistribution studies. Thus, lack of longer residence time of the competing molecule and its uptake in nontarget tissues including kidney could result in less efficient blocking of the radioligand uptake in tumor unlike large molecules such as antibodies, which have much longer circulation times in vivo. 46 Small-animal PET/CT studies with all three radiolabeled peptides demonstrated reasonable tumor uptake and retention. In spite of similar tumor uptake by these peptides, differences in uptake and retention of these compounds in nontarget tissues were found. For the 64 Cu-DO3A-peptide, the image revealed significant activity in the liver, gastrointestinal tract, and the kidneys. The image obtained with Cu-NO2A-peptides, however, demonstrated relatively reduced activity in the liver and the gastrointestinal tract with comparable retention in the kidneys. Likewise, biodistribution and imaging studies with 64 Cu-CB-TE2A-Y3-TATE, a somatostatin receptor targeting peptide, showed low uptake in liver and blood and more in the kidneys. 31 Recent studies with . 47 Taken together, Cu-NO2A-GSG-KCCYSL. Thus, CB-TE2A and NO2A-peptides appear to be better candidates for application as diagnostic PET agents for EGFR-2 expressing breast cancers.
